Keros Therapeutics (KROS) Current Assets (2019 - 2026)

Keros Therapeutics (KROS) has reported Current Assets for 8 consecutive years, with $266.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets fell 63.58% year-over-year to $266.9 million; the trailing twelve-month figure through Jun 2026 stood at $266.9 million (down 63.58% YoY), and the FY2025 full-year result was $315.4 million, down 46.44% from the prior year.
• Current Assets retreated to $266.9 million in Q2 2026 per KROS's latest filing, from $315.4 million in the prior quarter.
• Across five years, Current Assets topped out at $759.5 million in Q1 2025 and bottomed at $222.4 million in Q2 2022.
• Historically, Current Assets has averaged $421.4 million across 5 years, with a median of $347.3 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Current Assets soared 81.33% in 2024, then slumped 63.58% in 2026.
• Over 5 years, Current Assets stood at $285.8 million in 2022, then rose by 21.53% to $347.3 million in 2023, then surged by 69.57% to $588.9 million in 2024, then sank by 46.44% to $315.4 million in 2025, then retreated by 15.39% to $266.9 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $266.9 million, $315.4 million, and $719.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.